DGCI bans 10 Chinese firms from importing to India; reports
The DCGI has banned import of raw materials from 10 Chinese companies which lacked mandatory manufacturing standards, according to The Economic Times of India.
Clotrimazole, mefenamic acid and sulphadoxine are among the affected raw materials. The Drug Controller General of India (DGCI) cancelled the registration of firms producing these and other materials for supplying them without having mandatory drug manufacturing standards.
Some of the affected products are supplied by a limited number of companies creating the possibility of shortages. Lalit Kumar Jain, chairman at SMPIC, said the bans created a chance for Indian firms to boost sales of certain active pharmaceutical ingredients (API).
